Advertisement
Screener

PROMIS NEUROSCIENCES INC. (PMN) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

PROMIS NEUROSCIENCES INC. Stock-Based Compensation

PROMIS NEUROSCIENCES INC. (PMN) reported Stock-Based Compensation of $598.32 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-13

  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $408.89K, a 92.86% increase year-over-year.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $189.43K, a 22.78% decline year-over-year.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $203.17K, a 67.40% decline year-over-year.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $197.15K, a 62.88% increase year-over-year.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for fiscal 2025 was $857.63K, a 3.85% increase from fiscal 2024.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for fiscal 2024 was $825.81K, a 204.12% increase from fiscal 2023.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for fiscal 2023 was $271.54K, a 44.31% decline from fiscal 2022.
  • PROMIS NEUROSCIENCES INC. share-based payment arrangement, noncash expense for fiscal 2022 was $487.63K, a 5.43% decline from fiscal 2021.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 month
2026-06-30$408.89K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$598.32K
10-Q · filed 2026-08-13
$801.49K
derived: sum of 3 quarters · filed 2026-08-13
$998.64K
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$189.43K
10-Q · filed 2026-05-12
$392.60K
derived: sum of 2 quarters · filed 2026-05-12
$589.74K
derived: sum of 3 quarters · filed 2026-05-12
$801.76K
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$203.17K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$400.32K
derived: sum of 2 quarters · filed 2026-03-25
$612.33K
derived: sum of 3 quarters · filed 2026-08-13
$857.63K
10-K · filed 2026-03-25
2025-09-30$197.15K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$409.16K
derived: sum of 2 quarters · filed 2026-08-13
$654.46K
10-Q · filed 2025-11-12
$1.28M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$212.01K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$457.31K
10-Q · filed 2026-08-13
$1.08M
derived: sum of 3 quarters · filed 2026-08-13
$1.20M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$245.29K
10-Q · filed 2026-05-12
$868.48K
derived: sum of 2 quarters · filed 2026-05-12
$989.52K
derived: sum of 3 quarters · filed 2026-05-12
$1.01M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$623.19K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$744.23K
derived: sum of 2 quarters · filed 2026-03-25
$762.22K
derived: sum of 3 quarters · filed 2026-03-25
$825.81K
10-K · filed 2026-03-25
2024-09-30$121.04K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$139.03K
derived: sum of 2 quarters · filed 2025-11-12
$202.62K
10-Q · filed 2025-11-12
$207.46K
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$18.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$81.58K
10-Q · filed 2025-08-13
$86.42K
derived: sum of 3 quarters · filed 2025-08-13
$86.42K
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$63.58K
10-Q · filed 2025-05-12
$68.42K
derived: sum of 2 quarters · filed 2025-05-12
$68.42K
derived: sum of 3 quarters · filed 2025-05-12
$202.62K
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$4.84K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$4.84K
derived: sum of 2 quarters · filed 2025-03-31
$139.03K
derived: sum of 3 quarters · filed 2025-03-31
$271.54K
10-K · filed 2025-03-31
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$134.19K
derived: sum of 2 quarters · filed 2024-11-14
$266.70K
10-Q · filed 2024-11-14
$405.47K
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$134.19K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$266.70K
10-Q · filed 2024-08-08
$405.47K
derived: sum of 3 quarters · filed 2024-08-08
$514.05K
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$132.51K
10-Q · filed 2024-05-14
$271.28K
derived: sum of 2 quarters · filed 2024-05-14
$379.86K
derived: sum of 3 quarters · filed 2024-05-14
$495.27K
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$138.77K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$247.35K
derived: sum of 2 quarters · filed 2024-04-01
$362.76K
derived: sum of 3 quarters · filed 2024-04-01
$487.63K
10-K · filed 2024-04-01
2022-09-30$108.58K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$224.00K
derived: sum of 2 quarters · filed 2023-11-14
$348.86K
10-Q · filed 2023-11-14
$467.01K
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$115.41K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$240.28K
10-Q · filed 2023-08-14
$358.43K
derived: sum of 3 quarters · filed 2023-08-14
$548.05K
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$124.86K
10-Q · filed 2023-05-15
$243.01K
derived: sum of 2 quarters · filed 2023-05-15
$432.64K
derived: sum of 3 quarters · filed 2023-05-15
2021-12-31$118.15K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08
$307.78K
derived: sum of 2 quarters · filed 2023-03-08
$515.63K
10-K · filed 2023-03-08
2021-09-30$189.63K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$397.48K
10-Q · filed 2022-11-14
2021-06-30$207.85K
10-Q · filed 2022-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Anixa Biosciences Inc (ANIX)United States$0.096B
Equillium, Inc. (EQ)United States$0.109B-11.27
GENELUX Corp (GNLX)United States$0.110B-3.83
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51